[go: up one dir, main page]

WO2003020708A1 - Produits intermediaires de zosinamide et synthese y relative - Google Patents

Produits intermediaires de zosinamide et synthese y relative Download PDF

Info

Publication number
WO2003020708A1
WO2003020708A1 PCT/US2002/027593 US0227593W WO03020708A1 WO 2003020708 A1 WO2003020708 A1 WO 2003020708A1 US 0227593 W US0227593 W US 0227593W WO 03020708 A1 WO03020708 A1 WO 03020708A1
Authority
WO
WIPO (PCT)
Prior art keywords
bos
mixture
benzisoxazole
crystalline
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/027593
Other languages
English (en)
Inventor
Tamar Nidam
Marioara Mendelovici
Eduard Schwartz
Shlomit Wizel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to JP2003524979A priority Critical patent/JP2005506980A/ja
Priority to IL15823902A priority patent/IL158239A0/xx
Priority to CA002458905A priority patent/CA2458905A1/fr
Priority to EP02768748A priority patent/EP1430037A4/fr
Publication of WO2003020708A1 publication Critical patent/WO2003020708A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Definitions

  • the second method described in literature for zomsamide preparation includes the preparation of BOA starting f om 4-hydroxy-coumarin, followed by the sulfonation reaction of BOA to BOS.
  • the sulfonation reaction of the zonisamide intermediate i.e., BOA
  • the reagent chlorosulfonic acid is used in a large excess and it is also the reaction solvent.
  • the reactions of this synthetic method are shown in scheme 2:
  • the present invention provides a novel crystal form of BOS-Na Form ⁇ , characterized by an X-Ray Powder Diffraction (XRD) having the main peaks at about 5.3, 16.6, 21.3 and 26.7 ⁇ 0.2 degrees two theta.
  • XRD X-Ray Powder Diffraction
  • the present invention provides a novel crystal form of BOS-Na Form HI, characterized by a Furier Transform Infra Red Spectroscopy (FTIR) spectrum having the most characteristic peaks at about 3604, 1065, 812 and 696 cm '1 .
  • FTIR Furier Transform Infra Red Spectroscopy
  • Fig. 15 depicts the Furier Transform Infra Red Spectroscopy (FTIR) spectrum of BOS-Ba novel Form I.
  • FTIR Furier Transform Infra Red Spectroscopy
  • the sulfonation process for the Ac 2 O/H SO involves a reaction that is performed in polar and non-polar solvents.
  • the polar solvents include ethylacetate, ethylcellosolve, methylcellosolve, dichloroethane, dichloromethane, chloroform or mixture thereof and the like.
  • the non-polar solvents include toluene, heptane, hexanes, alkanes or mixtures thereof and the like.
  • Example 4 Preparation of BOS-Na: CISO3H in dichloroethane In a 100 mL three necked flask, equipped with thermometer, condenser and mechanical stirrer was charged dichloroethane (25 mL), 2.5 mL ClSO 3 H (1.3 eq.), and BOA (5 grams). The reaction mixture was heated at reflux for 1.5 hours.
  • BOS-Na monohydrate novel form I is characterized by the following X-Ray Diffraction main peaks at about 5.0, 15.7, 16.5, 17.3, 18.6, 19.1, 19.7, 21.5, 22.8, 23.2, 23.5 and 24.3 ⁇ 0.2 degrees two theta.
  • Water content measured by Karl-Fischer (KF) method is in agreement with TGA weight loss step and is about 7%. This water content is coincident with the expected water content of monohydrate.
  • DTG DTG profile of BOS-Ba novel form I is characterized by an endothermic peak at about 200°C. A weight loss step of about 3.5% is observed in this temperature range.
  • reaction mixture was cooled to room temperature and ice was added.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne une nouvelle sulfonation d'un produit intermédiaire de zosinamide. Elle concerne en particulier le processus de sulfonation au moyen d'acide chlorosulfonique, ou d'anhydride acétique et d'acide sulfurique dans un solvant organique. L'invention concerne en outre des formes cristallines de l'acide benzisoxazole méthane sulfonique (BOS-H) et de ses sels (BOS-Na, BOS-Ca, et BOS-Ba) et de nouveaux procédés de préparation de ces composés.
PCT/US2002/027593 2001-08-30 2002-08-29 Produits intermediaires de zosinamide et synthese y relative Ceased WO2003020708A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003524979A JP2005506980A (ja) 2001-08-30 2002-08-29 ゾニスアミド中間体及び合成
IL15823902A IL158239A0 (en) 2001-08-30 2002-08-29 Zonisamide intermediate and synthesis
CA002458905A CA2458905A1 (fr) 2001-08-30 2002-08-29 Produits intermediaires de zosinamide et synthese y relative
EP02768748A EP1430037A4 (fr) 2001-08-30 2002-08-29 Produits intermediaires de zosinamide et synthese y relative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31610901P 2001-08-30 2001-08-30
US60/316,109 2001-08-30
US34443901P 2001-10-24 2001-10-24
US60/344,439 2001-10-24

Publications (1)

Publication Number Publication Date
WO2003020708A1 true WO2003020708A1 (fr) 2003-03-13

Family

ID=26980239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027593 Ceased WO2003020708A1 (fr) 2001-08-30 2002-08-29 Produits intermediaires de zosinamide et synthese y relative

Country Status (5)

Country Link
EP (1) EP1430037A4 (fr)
JP (1) JP2005506980A (fr)
CA (1) CA2458905A1 (fr)
IL (1) IL158239A0 (fr)
WO (1) WO2003020708A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030738A1 (fr) * 2003-09-29 2005-04-07 Suven Life Sciences Limited Procede ameliore de fabrication d'intermediaires utilises pour l'obtention de zonisamide
US6900333B2 (en) 2003-01-13 2005-05-31 Dainippon Pharmaceutical Co., Ltd. Process for the preparation of 1, 2-dichlorethane free crystals of zonisamide
EP1472236A4 (fr) * 2002-02-22 2006-04-19 Teva Pharma Procede servant a la preparation de chlorure de benzisoxazole methane sulfonyle et a son amidation pour former un zonisamide
US7375233B2 (en) 2005-12-16 2008-05-20 Apotex Pharmachem Inc. Process for the preparation of zonisamide and the intermediates thereof
US7745471B2 (en) 2004-06-18 2010-06-29 Chemagis Ltd. Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512791A1 (fr) * 2003-01-10 2004-07-29 Dipharma S.P.A. Procede de preparation d'acide methanesulfonique benzo[d]isoxazol-3-yle et ses intermediaires
TW200732312A (en) * 2005-09-16 2007-09-01 Dainippon Sumitomo Pharma Co Method for sulfonation of 1,2-benzisoxazole-3-acetic acid
US10189763B2 (en) 2016-07-01 2019-01-29 Res Usa, Llc Reduction of greenhouse gas emission
WO2018004994A1 (fr) 2016-07-01 2018-01-04 Res Usa, Llc Réacteur à membrane à lit fluidisé
US9981896B2 (en) 2016-07-01 2018-05-29 Res Usa, Llc Conversion of methane to dimethyl ether

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377057A (en) * 1976-12-16 1978-07-08 Dainippon Pharmaceut Co Ltd 1,2-benxisoxazole derivatives
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS54163570A (en) * 1978-06-12 1979-12-26 Dainippon Pharmaceutical Co Benzooxazole derivative
JPS54163823A (en) * 1978-06-12 1979-12-26 Dainippon Pharmaceutical Co Antiiepileptic agent based on 33sulphamoylmethyll 1*22benzisoxazole
FR2428033A1 (fr) * 1978-06-09 1980-01-04 Dainippon Pharmaceutical Co Nouveaux derives heterocycliques de methanesulfonamide utiles notamment comme anticonvulsivants et leur procede de preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373229A4 (fr) * 2001-03-02 2005-05-04 Teva Pharma Procede de preparation d'acide 1,2-benzisoxazole-3-acetique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377057A (en) * 1976-12-16 1978-07-08 Dainippon Pharmaceut Co Ltd 1,2-benxisoxazole derivatives
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
FR2428033A1 (fr) * 1978-06-09 1980-01-04 Dainippon Pharmaceutical Co Nouveaux derives heterocycliques de methanesulfonamide utiles notamment comme anticonvulsivants et leur procede de preparation
JPS54163570A (en) * 1978-06-12 1979-12-26 Dainippon Pharmaceutical Co Benzooxazole derivative
JPS54163823A (en) * 1978-06-12 1979-12-26 Dainippon Pharmaceutical Co Antiiepileptic agent based on 33sulphamoylmethyll 1*22benzisoxazole

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1430037A4 *
UNO ET AL.: "Studies on 3-substituted 1,2-benzisoxazole derivatives. VII. Catalytic reduction of 3-sulfamoylmethyl-1,2-benzisoxazole and reactions of the resulting products", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 30, no. 1, 1981, pages 333 - 335, XP002959509 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472236A4 (fr) * 2002-02-22 2006-04-19 Teva Pharma Procede servant a la preparation de chlorure de benzisoxazole methane sulfonyle et a son amidation pour former un zonisamide
US6900333B2 (en) 2003-01-13 2005-05-31 Dainippon Pharmaceutical Co., Ltd. Process for the preparation of 1, 2-dichlorethane free crystals of zonisamide
WO2005030738A1 (fr) * 2003-09-29 2005-04-07 Suven Life Sciences Limited Procede ameliore de fabrication d'intermediaires utilises pour l'obtention de zonisamide
US7745471B2 (en) 2004-06-18 2010-06-29 Chemagis Ltd. Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide
US7375233B2 (en) 2005-12-16 2008-05-20 Apotex Pharmachem Inc. Process for the preparation of zonisamide and the intermediates thereof

Also Published As

Publication number Publication date
JP2005506980A (ja) 2005-03-10
CA2458905A1 (fr) 2003-03-13
IL158239A0 (en) 2004-05-12
EP1430037A4 (fr) 2004-11-17
EP1430037A1 (fr) 2004-06-23

Similar Documents

Publication Publication Date Title
KR930003492B1 (ko) 7-할로-7-데옥시린코마이신, 클린다마이신 및 이들의 유사체의 제조 방법
US6841683B2 (en) Sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms
EA022099B1 (ru) Способы и интермедиаты для получения ингибиторов интегразы
EP1430037A1 (fr) Produits intermediaires de zosinamide et synthese y relative
US7015330B2 (en) Sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms
EP1375487B1 (fr) Procede de production d'un compose d'acide quinoline-3-carboxylique
Papadopoulos Reactions of pyrrole with isocyanates. Preparation and reactions of N-ethoxy-carbonylpyrrole-2-carboxamide and pyrrole-1, 2-dicarboximide
US7109353B2 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
CA2545119A1 (fr) Procede de fabrication de zonisamide
KR870001922B1 (ko) 이미다졸 유도체의 제조방법
EP0149229B1 (fr) 3-(Gamma-chloropropyl)-6-fluor-1,2-benzisoxazole, procédé pour le préparer et son utilisation comme intermédiaire
EP0131472B1 (fr) Composition contenant du 5-mercapto-1,2,3-thiadiazole et leur procédé de préparation
JPS6140661B2 (fr)
CZ2002146A3 (cs) Způsob přípravy 2-methoxy-4-(N-terc-butylaminokarbonyl)-benzensulfonylchloridu
TWI903000B (zh) 1,1,1-參(4-羥基-3,5-二甲基苯基)乙烷之結晶體及其製造方法
HU192583B (en) Process for preparing 4-quinolines
US20060009644A1 (en) Novel crystalline forms of sodium 1,2-benzisoxazole-3-methanesulfonate, processes of preparing same and use thereof in the synthesis of zonisamide
JPH0667942B2 (ja) テトラヒドロ３環式化合物
US4593101A (en) Process for the preparation of 4-quinolinones
SU615859A3 (ru) Способ получени 6-дезокси-6-азидо-7,8-дигидроизоморфина или 6-дезокси-6-азидо-14-окси-7,8-дигидроизоморфина или их 3-алкиокси- или 3-алканоилокси-производных или их солей
WO2025243914A1 (fr) Cristaux de 2,2-bis(4,4-bis(3-t-butyl-4-hydroxyphényl)cyclohexyl)propane et leur procédé de production
JPH0586042A (ja) ２−メルカプト−フエノチアジンの製造方法
SU449046A1 (ru) Способ получени триэтилсилиловых эфиров 17 -оксистероидов
CH647525A5 (fr) Solvats cristallins du 7-phenoxyacetamido-3-hydroxy-3-cephem-4-carboxylate de 4'-nitrobenzyle et de son sulfoxyde, et leur preparation.
CA2512791A1 (fr) Procede de preparation d'acide methanesulfonique benzo[d]isoxazol-3-yle et ses intermediaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 158239

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2458905

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003524979

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002768748

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002768748

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002768748

Country of ref document: EP